0001493152-26-046867.txt : 20261013 0001493152-26-046867.hdr.sgml : 20261013 20261013170309 ACCESSION NUMBER: 0001493152-26-046867 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20261013 DATE AS OF CHANGE: 20261013 EFFECTIVENESS DATE: 20261013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vimy Pharmaceuticals Inc. CENTRAL INDEX KEY: 0002159983 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-601025 FILM NUMBER: 261457563 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 2 BLOOR STREET WEST, SUITE 2002 CITY: TORONTO PROVINCE COUNTRY: A6 ZIP: M4W1J5 BUSINESS PHONE: 4162544774 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 2 BLOOR STREET WEST, SUITE 2002 CITY: TORONTO PROVINCE COUNTRY: A6 ZIP: M4W1J5 D 1 primary_doc.xml X0708 D LIVE 0002159983 Vimy Pharmaceuticals Inc. 2 BLOOR STREET WEST SUITE 2002 TORONTO A6 ONTARIO, CANADA M4W1J5 416-254-4774 ONTARIO, CANADA None None Corporation true 2024 David John Suchon 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Executive Officer Director Chief Executive Officer Farris Smith 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Executive Officer Director President and Chair Darryl Firsten 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Riccardo Trecroce 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Christopher Burkett 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Pharmaceuticals Decline to Disclose 06b false 2026-09-28 false true true The Issuer sold subscription receipts, which will be converted into shares of the Issuer without consideration upon the closing of the transaction. 0 Beacon Securities US Limited 000306613 Beacon Securities Limited None 66 Wellington Street West Suite 4050 Toronto A6 ONTARIO, CANADA M5K1H1 NY NEW YORK false 1010798 1010798 0 The total offering amount was $1,432,200 in Canadian dollars. The U.S. dollar value above is based on the Federal Reserve exchange rate on September 28, 2026 of $1.4169 CAD per USD. false 7 150365 true 0 Consists of (i) $34,583 cash fee; (ii) President's List purchasers: $2,757 cash fee and $2,757 in options, each 3% of such sales; (iii) other purchasers: $55,134 cash fee and $55,134 in options, each 6% of such sales. CAD converted to USD at the same rate 0 false Vimy Pharmaceuticals Inc. /s/ David Suchon David Suchon Chief Executive Officer 2026-10-13